If ERβ expression abnormalities represent a critical step in the development and progression of several cancers including ovarian cancer, its re-expression by genetic engineering, as well as the use of targeted ERβ therapies, may constitute important new therapeutic approaches. The gene discussed is ESR2; the disease is ovarian carcinoma.